TL;DR: 🔴 Mostly noninferior, but harm in one subgroup — HFNO was noninferior to NIV in 4 of 5 ARF etiologies, but was WORSE specifically in immunocompromised patients with hypoxemia (OR 2.56).
1. Publication
- Title: High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial
- Acronym: RENOVATE
- Year & Journal: JAMA, published December 10, 2024
- Citation: RENOVATE Investigators and the BRICNet Authors. JAMA. 2024. doi:10.1001/jama.2024.26244
2. Context & Rationale
Background: HFNO and NIV are both used for acute respiratory failure (ARF), but HFNO offers better comfort/tolerance. Whether HFNO is noninferior to NIV across the diverse etiologies of ARF (hypoxemic, immunocompromised, COPD exacerbation, cardiogenic pulmonary edema, post-extubation) was unresolved.
Research Question/Hypothesis: Across 5 distinct ARF patient groups, is HFNO noninferior (or superior) to NIV for reducing intubation or death within 7 days?
3. Design & Methods
- Study Type: Adaptive, Bayesian, multicenter, randomized clinical trial with frequent interim analyses allowing individual patient groups to stop for futility, noninferiority, or superiority
- Setting & Centers: Brazil (BRICNet); Nov 2019–Feb 2024
- Population: 5 groups — hypoxemic ARF (non-immunocompromised), immunocompromised with hypoxemia, COPD exacerbation, acute cardiogenic pulmonary edema, and post-extubation ARF; 2731 assessed
- Intervention: HFNO
- Comparator: NIV (pressure support + PEEP); rescue NIV permitted per protocol for COPD/cardiogenic edema groups without being a protocol violation
- Statistical Power & Follow-Up: Primary: intubation or death within 7 days, analyzed per patient group.
4. Key Results
Patient Group | Result | Notes |
Hypoxemic ARF (non-immunocompromised) | Noninferior | — |
Immunocompromised with hypoxemia | Worse with HFNO | OR 2.56 (95% CrI 1.14–5.68) — did NOT meet noninferiority; signal of harm |
COPD exacerbation | Noninferior | — |
Acute cardiogenic pulmonary edema | Noninferior | — |
Post-extubation ARF | Noninferior | — |
Comfort (overall) | Significantly better with HFNO | Across entire population |
Overall: HFNO noninferior in 4 of 5 groups; NOT noninferior (worse) specifically in immunocompromised patients with hypoxemia.
5. Internal Validity Assessment
Bayesian adaptive design with frequent interim analyses allowing group-specific stopping decisions (futility/noninferiority/superiority) — methodologically sophisticated. Overall: Strong — large (2731-assessed), well-designed, and the differential result (harm signal specifically in immunocompromised hypoxemic patients) is a genuinely important, clinically actionable finding rather than a uniform result.
6. External Validity Assessment
Brazilian, multicenter population spanning ICU, ward, and ED settings across 5 distinct ARF etiologies — excellent generalizability given the breadth of patient groups tested, though single-country.
7. Strengths & Limitations
Strengths: Adaptive Bayesian design efficiently tested 5 distinct patient populations; identified an important differential (harm) signal in immunocompromised patients that a single pooled analysis might have masked; large sample.
Limitations: Single-country trial; subgroup analyses, while prespecified as separate patient groups, still carry some of the usual subgroup-analysis caveats regarding precision (wide CrI in the immunocompromised group).
8. Interpretation & Practice Impact
Supports HFNO as a reasonable, more comfortable first-line respiratory support choice for most ARF etiologies (COPD, cardiogenic edema, post-extubation, general hypoxemic ARF) — but specifically NOT for immunocompromised patients with hypoxemia, where NIV appears superior and HFNO showed a concerning harm signal.
9. Controversies & Subsequent Evidence
Two accompanying JAMA editorials engage directly with this trial: "Is High-Flow Oxygen the Standard for All Patients With Acute Respiratory Failure?" (Frat, Le Pape, Thille) and "Reevaluating Respiratory Support in Acute Respiratory Failure" (Freund, Vromant) — both emphasizing that the immunocompromised-hypoxemia subgroup result argues against a one-size-fits-all HFNO-first policy.
10. Summary & Executive Takeaway
Summary: RENOVATE, an adaptive Bayesian trial in Brazil, randomized patients across 5 ARF etiology groups to HFNO or NIV. HFNO was noninferior in 4 groups (hypoxemic ARF, COPD, cardiogenic edema, post-extubation) and significantly more comfortable overall, but was associated with worse outcomes in immunocompromised patients with hypoxemia (OR 2.56, 95% CrI 1.14-5.68).
Overall Takeaway: HFNO can serve as a comfortable, effective first-line respiratory support choice for most ARF etiologies, but NIV should remain preferred specifically for immunocompromised patients with hypoxemia — a genuinely important, etiology-specific practice nuance rather than a blanket "HFNO is fine for everyone" conclusion.
11. Bibliography
- Frat JP, Le Pape S, Thille AW. Is High-Flow Oxygen the Standard for All Patients With Acute Respiratory Failure? [editorial]. JAMA. 2024.
- Freund Y, Vromant A. Reevaluating Respiratory Support in Acute Respiratory Failure [editorial]. JAMA. 2024.